Novo Nordisk

Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Bidding War Sends Metsera Shares Higher Metsera’s share price has been on a roller-coaster amid takeover speculation. In late September, Pfizer agreed to buy Metsera for $47.50 per share in cash (about

30 October 2025

Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk hijacks Pfizer’s Metsera deal with a $9B bid – obesity-drug war heats up

Novo’s counter-offer details Novo Nordisk’s proposal is unsolicited, meaning Metsera’s board and shareholders will now review it against Pfizer’s agreement. Novo emphasizes that Metsera’s experimental therapies would be “complementary” to its own

30 October 2025

Biotechnology · Industry News · Mergers & Acquisitions · NYSE:NVO · NYSE:PFE · Obesity Drugs · Pharmaceuticals

Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Boardroom Shake-Up Spurs Investor Nerves Novo’s stock slide accelerated this week amid a dramatic boardroom conflict. On Oct. 21, the Novo Nordisk Foundation (the company’s controlling shareholder) announced it would remove chair

22 October 2025

Business Rivalry · Corporate News · NYSE:NVO · Pharmaceuticals · Stock Market · Weight Loss

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s Weight-Loss Crown at Risk? NVO Stock Slumps Amid Surprise Deals – What’s Next

NVO Stock Slides as Weight-Loss Hype Cools Novo Nordisk’s stock has been on a wild ride. After becoming Europe’s most valuable company in 2022–2023 on the back of its smash-hit obesity drug

17 October 2025

Healthcare · Industry News · NASDAQ:AKRO · NASDAQ:OMER · NYSE:LLY · NYSE:NVO · Pharmaceuticals · Stock Market · Weight Loss

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Novo Nordisk Licensing Deal Sparks Rally On Oct. 15, Novo Nordisk (NYSE: NVO) and Omeros announced a landmark deal licensing zaltenibart (OMS906), Omeros’s experimental MASP-3 inhibitor for rare blood/kidney diseases investor.omeros.com. Under

15 October 2025

Financial Analysis · Investment News · Mergers & Acquisitions · NASDAQ:OMER · NYSE:NVO · Pharma Industry · Stock Market

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Deal Details: Novo Licenses Omeros’s MASP-3 Inhibitor On Oct. 15, Novo Nordisk and Seattle-based Omeros announced a definitive asset purchase and license agreement. Under the terms, Novo gains exclusive global rights to zaltenibart

15 October 2025

Biotech Industry · Business Analysis · Mergers & Acquisitions · NASDAQ:AKRO · NASDAQ:OMER · NYSE:NVO · Pharma News · Rare Diseases

Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Sources: Akero Therapeutics investor materials; Novo Nordisk press statements; Reuters, TS2.tech and FierceBiotechnews reports ts2.tech ts2.tech fiercebiotech.com; MarketBeat and DirectorsTalk analyst surveys marketbeat.com directorstalkinterviews.com; Economic Times deal summary economictimes.indiatimes.com economictimes.indiatimes.com; Business Wire legal alert businesswire.com businesswire.com; and TradingView market data marketbeat.com tradingview.com.

9 October 2025

Biotech News · Investment Insights · Mergers & Acquisitions · NASDAQ:AKRO · NYSE:NVO · Pharma Industry · Stock Market

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Forecast: Experts believe that within the next 2–3 years, we’ll know if Novo’s gamble pays off. Phase 3 readouts for efruxifermin are anticipated in 2026, and Novo hopes to launch the drug by late this

9 October 2025

Drug Development · Healthcare Industry · Liver Health · Medical Innovation · NASDAQ:AKRO · NYSE:NVO · Pharmaceuticals